Oct 2026· Journal of Chemical Theory and Computation· 0 citations· 47 references
TL;DR
This work demonstrates the application of a combination of induced fit docking and free energy perturbation to structurally enable several of the most common anti-targets: cytochrome P450 isoforms 3A4 and 2D6, the hERG ion channel, and PXR.
Abstract
The development of a small molecule suitable for clinical use involves optimization of ligand binding to an identified target protein but also frequently the reduction of binding to a variety of anti-target proteins known to pose translational risk. These anti-targets, often referred to as ADMET proteins, often contain large, highly flexible binding sites, leading to promiscuous binding of small molecules. This property often frustrates efforts to execute structure-based design against these anti-targets. Here, we demonstrate the application of a combination of induced fit docking and free energy perturbation to structurally enable several of the most common anti-targets: cytochrome P450 isoforms 3A4 and 2D6, the hERG ion channel, and PXR. Crucially, the enforcement of a consensus binding mode across a congeneric series allowed for the efficient exploration of a wide range of receptor conformational space. Results are presented for both public retrospective datasets and prospective application in active drug discovery programs.
Protein–protein interactions (PPIs) represent an attractive class of therapeutic targets, yet the discovery of PPI inhibitors remains challenging because PPI interfaces are typically shallow and lack well-defined binding pockets. Moreover, target binding alone does not necessarily translate into functional inhibition,...
Hee Myeong Wang, Seung-Jun Jang, Sanggil Kim et al.· RSC Chemical Biology· 0 citations
In the MC38 syngeneic tumor model, both Z21 and Z28, when used in combination with anti-PD-1, reduced tumor growth, accompanied by increased frequency of tumor-infiltrating CD8+ T cells, and the in vitro and in vivo results support Z21 and Z28 as prioritized small-molecule candidates for further investigations.
Ke-Jia Ren, Peng-Shan Li, Jia-Cheng Liu et al.· Bioorganic chemistry (Print)· 0 citations
Off-target protein binding is a major source of adverse effects for small-molecule drugs, yet most structure-based molecular design methods focus on generating selective compounds de novo rather than improving the selectivity of existing, well- characterized drugs. We introduce specificity optimization (SpecOpt), a mol...
This review covers the aspects of SBDD approach, traditional methods of protein structure determination and limitations that have restricted the application of this methodology, and addresses the use of AlphaFold models in major drug discovery processes including target identification, binding site prediction, molecula...
M. Pathak· European journal of medicina...· 0 citations
Identifying synthetically accessible, potent ligands from vast chemical space remains a major challenge in drug discovery, particularly because experimental synthesis and testing are costly and low throughput. Here, we present a fully open-source computational–experimental workflow that integrates fragment-based de nov...
Linking small molecules that bind adjacent sites on a target is a promising strategy for developing compounds with tight binding affinities. ATP-allosteric bivalent inhibitors (AABIs) of the epidermal growth factor receptor (EGFR) have provided new insights into efficient linker design where large potency gains can be...
Kishan B. Patel, I. A. Akinwumi, Tess M. Weber et al.· Journal of Medicinal Chemist...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.